1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

HHS Nominee Price's Stock Picks To Surface At Confirmation Hearings

 
• By Sue Darcey

Questions about US Health and Human Services Secretary nominee Tom Price's investments over the last year – including in Zimmer Biomet – and overlapping legislation he has introduced are likely to be raised at confirmation hearing before the Senate HELP Committee this week. However, Zimmer Biomet and other device firms have been trying to profit from the business models that Price opposes.

Leaders of a key US Senate health committee are expected to grill incoming President Donald Trump's pick for Health and Human Services Secretary, Rep. Tom Price, R-Ga., this week about his investments in health-care firms over the past year, including in the orthopedic device firm Zimmer Biomet Holdings Inc.

Among the issues that have been raised is that the HHS Secretary-nominee purchased between $1,001 to $15,000 worth of Zimmer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

NeuroOne Prepares To Launch Trigeminal Nerve Ablation System

 
• By Elizabeth Orr

The US FDA has cleared NeuroOne's OneRF trigeminal nerve ablation system for the treatment of trigeminal neuralgia. This minimally invasive method utilizes radio frequency energy to alleviate pain, offering an alternative to traditional medications and surgeries. A fall commercial launch is planned.

Warning Letters - July 2025

The US FDA posted three warning letters in July, covering medical supply kits, wearables and orthopedics.

Nyxoah Launches FDA-Cleared Genio System For OSA As Rival Inspire Files Patent Suit

 
• By Marion Webb

After receiving FDA clearance for its Genio sleep apnea implant, Nyxoah plans a major US rollout despite a patent suit from rival Inspire Medical. Genio offers bilateral nerve stimulation as a CPAP alternative, with strong trial results.